Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Prepaid Assets (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Prepaid Assets for 15 consecutive years, with $115.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 82.08% year-over-year to $115.8 million, compared with a TTM value of $115.8 million through Dec 2025, up 82.08%, and an annual FY2025 reading of $115.8 million, up 82.08% over the prior year.
  • Prepaid Assets was $115.8 million for Q4 2025 at Neurocrine Biosciences, up from $68.2 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $121.7 million in Q3 2024 and bottomed at $33.8 million in Q1 2021.
  • Average Prepaid Assets over 4 years is $91.5 million, with a median of $100.6 million recorded in 2023.
  • Peak annual rise in Prepaid Assets hit 82.08% in 2025, while the deepest fall reached 43.96% in 2025.
  • Year by year, Prepaid Assets stood at $50.5 million in 2021, then skyrocketed by 93.66% to $97.8 million in 2023, then tumbled by 34.97% to $63.6 million in 2024, then skyrocketed by 82.08% to $115.8 million in 2025.
  • Business Quant data shows Prepaid Assets for NBIX at $115.8 million in Q4 2025, $68.2 million in Q3 2025, and $120.7 million in Q2 2025.